Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

B-cell Malignancies Clinical Trial

Official title:

A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02343120
• Other study ID #: BGB-3111-AU-003
• Secondary ID: 2016-003364-39
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 4, 2014
• Est. completion date: March 31, 2021

Study information

• Verified date: April 2022
• Source: BeiGene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluated the safety, tolerability, pharmacokinetic profile and efficacy of BGB-3111 in participants with B-cell lymphoid malignancies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 385
• Est. completion date: March 31, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Aged = 18 years, voluntarily consented to the study.

2. WHO classification defined B-lymphoid malignancy, with the exception of Burkitt lymphoma/leukemia, plasma cell myeloma, acute lymphoblastic leukemia, lymphoblastic lymphoma, and plasmablastic lymphoma.

3. Requirement for treatment in the opinion of the investigator.

4. Disease which has relapsed, or is refractory, following at least one line of therapy, with no therapy of higher priority available.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

6. Adequate hematologic function, as defined by neutrophils = 1.0 x 10^9/L and platelets = 50 x 10^9/L; participants with neutrophils < 1.0 x 10^9/L due to marrow infiltration are allowed to receive growth factors to bring pre-treatment neutrophils to = 1.0 x 10^9/L.

7. Adequate renal function, as defined by creatinine clearance of = 30 ml/min (as estimated by the Cockcroft-Gault equation or as measured by nuclear medicine scan or 24 hour urine collection).

8. Adequate liver function, as defined by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3 x upper limit of normal (ULN), and bilirubin = 1.5 x ULN (unless documented Gilbert's syndrome).

9. International normalized ratio (INR) = 1.5 and activated partial thromboplastin time (APTT) = 1.5 x ULN.

10. Female participants of childbearing potential and non-sterile males must practice at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, IUD or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.

11. Male participants must not donate sperm from initial study drug administration, until 90 days after drug discontinuation.

Exclusion Criteria:

1. Current central nervous system (CNS) involvement by disease

2. Current histologically transformed disease.

3. Prior Bruton's tyrosine kinase (BTK) inhibitor treatment.

4. Allogeneic stem cell transplantation within 6 months, or has active graft-versus-host disease (GVHD) requiring ongoing immunosuppression.

5. Receipt of the following treatment prior to first dose of zanubrutinib:

corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 2 weeks, monoclonal antibody within 4 weeks.

6. Not recovered from toxicity of any prior chemotherapy to grade = 1.

7. History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.

8. Uncontrolled systemic infection requiring parenteral anti-microbial therapy.

9. Major surgery in the past 4 weeks.

10. Known HIV, or active hepatitis B or hepatitis C infection (detected positive by PCR).

11. Cardiovascular disease resulting in New York Heart Association function status of = 3.

12. Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participating in the study.

13. Inability to comply with study procedures.

14. On medications which are cytochrome P450 (CYP) 3A inhibitors.

Related Conditions & MeSH terms

• B-cell Malignancies
• Neoplasms

Intervention

Drug:
• Zanubrutinib
Oral administration by capsule

Locations

Country	Name	City	State
Australia	Princess Alexandra Hospital	Brisbane	Queensland
Australia	Monash Health	Clayton	Victoria
Australia	Concord Repatriation General Hospital	Concord	New South Wales
Australia	Austin Health	Heidelberg	Victoria
Australia	Royal Hobart Hospital	Hobart	Tasmania
Australia	St Vincent's Hospital	Melbourne	Victoria
Australia	Sir Charles Gairdner Hospital	Nedlands	Western Australia
Australia	Melbourne Health	Parkville	Victoria
Australia	Peter MacCallum Cancer Centre, East Melbourne	Parkville	Victoria
Australia	St George Hospital	Sydney	New South Wales
Australia	Westmead Hospital	Westmead	New South Wales
Italy	Policlinico S.Orsola Malpighi, AOU di Bologna	Bologna
Italy	Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda	Milano
Korea, Republic of	Dong-A University Medical Centre	Busan
Korea, Republic of	Inje University Busan Paik Hospital	Busan
Korea, Republic of	National Cancer Center	Goyang-si
Korea, Republic of	Samsung Medical Center	Seoul
New Zealand	North Shore Hospital	Auckland
United Kingdom	Derriford Hospital	Plymouth	Devon
United States	University of Michigan	Ann Arbor	Michigan
United States	Banner MD Anderson Cancer Centre	Gilbert	Arizona
United States	M.D. Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
BeiGene

Countries where clinical trial is conducted

United States,  Australia,  Italy,  Korea, Republic of,  New Zealand,  United Kingdom, 

References & Publications (4)

C.S. Tam M. Wang D. Simpson S. Opat G. Cull J. Munoz T.J. Phillips W. Kim S. Atwal R. Wei J. Huang R. Elstrom J. Trotman. UPDATED SAFETY AND EFFICACY DATA IN THE PHASE 1 TRIAL OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111). Hematological Oncology. 2019; 37(S2) DOI: https://doi.org/10.1002/hon.55_2630

Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 Mar;196(5):1209-1218. doi: 10.1111/bjh.17994. Epub 2021 Dec 16. — View Citation

Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24. — View Citation

Trotman J, Opat S, Gottlieb D, Simpson D, Marlton P, Cull G, Munoz J, Tedeschi A, Roberts AW, Seymour JF, Atwal SK, Yu Y, Novotny W, Holmgren E, Tan Z, Hilger JD, Huang J, Tam CS. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020 Oct 29;136(18):2027-2037. doi: 10.1182/blood.2020006449. Erratum in: Blood. 2021 Feb 25;137(8):1131. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part 1 and Part 2: Number of Participants With Adverse Events	Number of participants with adverse events and serious adverse events, including clinically relevant physical examinations and laboratory measurements	Up to approximately 6 years and 7 months
Primary	Part 1: Recommended Phase 2 Dose (RP2D) for Zanubrutinib	RP2D for zanubrutinib was the maximum tolerated dose (MTD) or less, which was determined by testing increasing doses up to 320 mg QD	Month 9
Secondary	Part 1 and Part 2: Area Under the Curve From Time 0 to the Last Sampling Time Point Within the Dose Interval (AUClast) of Zanubrutinib		Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Secondary	Part 1 and Part 2: Area Under the Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Zanubrutinib		Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Secondary	Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib		Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Secondary	Part 1 and Part 2: Maximum Observed Plasma Concentration (Cmax) After Administration of Zanubrutinib		Week 2 Day 1 pre-dose and 24 hours
Secondary	Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib		Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Secondary	Part 1 and Part 2: Time to Maximum Observed Plasma Concentration (Tmax) of Zanubrutinib		Week 2 Day 1 pre-dose and 24 hours
Secondary	Part 1 and Part 2: Apparent Terminal Half-life (t1/2) of Zanubrutinib		Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Secondary	Part 1 and Part 2: Apparent Clearance (CL/F) of Zanubrutinib		Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Secondary	Part 1 and Part 2: Apparent Volume of Distribution of Zanubrutinib During the Terminal Phase (Vz/F)		Week 1 Day 1 pre-dose, 0.5, 1, 2, 3, 4, and 8 hours
Secondary	Part 1 and Part 2: Overall Response Rate (ORR)	ORR is defined as the percentage of participants with partial or complete response (CR), as assessed by the investigator. For CLL/SLL, ORR includes partial response (PR) with lymphocytosis (PR-L) or better (includes PR-L, PR, nodular PR or nPR and CR with incomplete marrow recovery or CRi) and for MW, ORR includes minor response or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).	Up to 6 years and 7 months
Secondary	Part 1 and Part 2: Complete Response Rate (CRR)	CRR is defined as the percentage of participants who achieve a complete response, as assessed by the investigator. For CLL/SLL, CRR includes CRi or better. For WM, CRR includes very good partial response (VGPR) or better. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).	Up to 6 years and 7 months
Secondary	Part 1 and Part 2: Partial Response (PR) or Better	PR or better is defined as the percentage of participants who achieve a partial response or better, as assessed by the investigator. For CLL/SLL, includes PR, nPR, CRi, CR and for WM includes PR, VGPR, and CR. Efficacy results are reported for the B-cell malignancy subtypes chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and Waldenström macroglobulinemia (WM).	Up to 6 years and 7 months
Secondary	Part 1 and Part 2: Progression-free Survival (PFS)	PFS is defined as the time from the first dose date of study drug to the date of the earliest occurrence of progressive disease or death due to any cause, whichever occurs first. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).	Up to 6 years and 7 months
Secondary	Part 1 and Part 2: Overall Survival (OS)	OS is defined as the time from the date of the first dose to death due to any cause. Efficacy results are reported for each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).	Up to 6 years and 7 months
Secondary	Part 1 and Part 2: Duration of Response (DOR)	DOR for responders is defined as time from the date of the earliest qualifying response to the date of progressive disease or death for any cause, whichever occurs earlier. Efficacy results are reported for responders (defined as PR or better, except CLL/SLL and WM) in each of the B-cell malignancy subtypes: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; PR with lymphocytosis or better), Waldenstrom macroglobulinemia (WM; minor response or better), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), Richter's Transformation (RT), and Hairy cell leukemia (HCL).	Up to 6 years and 7 months
Secondary	Number of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy	Number of participants with greater than 75% BTK occupancy of zanubrutinib in peripheral blood mononuclear cells (PBMCs)	Week 1 Day 1 (W1D1) predose, W1D1 4 hours, W1D2 24 hours, W1D3 predose, and W2D1 predose